Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements.

Institutional review board approval and informed consent were obtained for this study. The aim of the study was to prospectively assess, in patients with lung cancer, the reproducibility of a quantitative whole tumor perfusion computed tomographic (CT) technique. Paired CT studies were performed in 10 patients (eight men, two women; mean age, 66 years) with lung cancer. Whole tumor permeability and blood volume were measured, and reproducibility was evaluated by using Bland-Altman statistics. Coefficient of variation of 9.49% for permeability and 26.31% for blood volume and inter- and intraobserver variability ranging between 3.30% and 6.34% indicate reliable assessment with this whole tumor technique.

[1]  Kazuo Miyasaka,et al.  Lung Tumors Evaluated With FDG-PET and Dynamic CT: The Relationship Between Vascular Density and Glucose Metabolism , 2002, Journal of computer assisted tomography.

[2]  E. Fishman,et al.  Application of CT in the investigation of angiogenesis in oncology. , 2000, Academic radiology.

[3]  R. Craen,et al.  Quantitative assessment of cerebral hemodynamics using CT: stability, accuracy, and precision studies in dogs. , 1999, Journal of computer assisted tomography.

[4]  T. Purdie,et al.  Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumour. , 2001, Physics in medicine and biology.

[5]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[7]  A. Padhani,et al.  Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.

[8]  M. Dewhirst,et al.  Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. , 1996, Cancer research.

[9]  V. Goh,et al.  Quantitative assessment of colorectal cancer perfusion using MDCT: inter- and intraobserver agreement. , 2005, AJR. American journal of roentgenology.

[10]  K. Miles,et al.  CT derived Patlak images of the human kidney. , 1999, The British journal of radiology.

[11]  K. Miles,et al.  CT measurements of capillary permeability within nodal masses: a potential technique for assessing the activity of lymphoma. , 1997, British Journal of Radiology.

[12]  F R Verdun,et al.  Using 80 kVp versus 120 kVp in perfusion CT measurement of regional cerebral blood flow. , 2000, AJNR. American journal of neuroradiology.

[13]  J. Yap,et al.  Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Martin A Lodge,et al.  Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[16]  D. Altman,et al.  Applying the right statistics: analyses of measurement studies , 2003, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[17]  R. Craen,et al.  A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. , 2000, AJNR. American journal of neuroradiology.

[18]  F. Eskens,et al.  Angiogenesis inhibitors in clinical development; where are we now and where are we going? , 2004, British Journal of Cancer.

[19]  K. Miles,et al.  Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules. , 2001, Radiology.

[20]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[21]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[22]  S. Hill,et al.  Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. , 1995, British Journal of Cancer.

[23]  Weijing Sun,et al.  Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Heiserman,et al.  Assessment of the reproducibility of postprocessing dynamic CT perfusion data. , 2004, AJNR. American journal of neuroradiology.

[25]  C. Yi,et al.  Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. , 2004, Radiology.